SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SCYNEXIS, Inc. on June 23, 2021. The report details the receipt of a second tranche of funding under a previously disclosed Loan and Security Agreement entered into on May 13, 2021, with Hercules Capital, Inc. and Silicon Valley Bank.
Key Financial Metrics
- Debt Financing: The company received an additional $10.0 million under its Term Loan facility.
- Total Facility Size: The aggregate principal amount of the Term Loan is up to $60.0 million.
- Tranche Structure: The loan is available in four tranches. The initial tranche of $20.0 million was received at closing; this filing confirms the receipt of the second tranche.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes
The material change reported is the disbursement of the second tranche of the Term Loan. This tranche became available upon the company receiving approval from the Food and Drug Administration (FDA) for ibrexafungerp for the treatment of vaginal yeast infections (the "First Performance Milestone").
Outlook, Risks, and Management Commentary
The release of the second tranche is contingent upon specific performance milestones, specifically FDA approval for the company's drug candidate. The filing references a prior 8-K from May 14, 2021, for further details on the Loan Agreement terms. No specific forward-looking guidance or risk factors beyond the milestone dependency are detailed in this specific text.
Key Facts for Investor Verification
- Verify the total outstanding debt balance following the $10.0 million disbursement.
- Confirm the specific terms, interest rates, and maturity dates of the Term Loan by reviewing the May 14, 2021, 8-K filing.
- Monitor the status of the remaining two tranches of the $60.0 million facility and their associated performance milestones.
- Validate the FDA approval status of ibrexafungerp for vaginal yeast infections as the trigger for this funding.